Mayne Pharma Group Limited announced the completion of the exclusive product licensing transaction with TherapeuticsMD, Inc. (TXMD) which was announced on 5 December 2022. Under the exclusive licence agreement Mayne Pharma has secured a portfolio of on-market women's health products from TXMD including three patent protected novel women's health products: ANNOVERA, IMVEXXY® and BIJUVA® and a portfolio of prenatal vitamins in the US as well as selected assets including inventory and regulatory filings to support the operation and commercialisation of the portfolio. Under the terms of the agreement, Mayne Pharma paid a cash consideration to TXMD of USD 140 million and a USD 13.1 million payment for acquired net working capital and pre-paid royalties.